-- Recently, the world's leading biotechnology service provider, Creative Biolabs, announced the latest upgrade to its OncoVirapy™ platform, launching an industry-leading, one-stop oncolytic virus enhancement service. This service aims to provide global research institutions and pharmaceutical companies with a full life-cycle solution from virus backbone design and efficacy enhancement to preclinical validation through cutting-edge genetic engineering, protein engineering, and nano-encapsulation technologies.
Precise "Enhancement": Breaking the Application Bottleneck of Oncolytic Viruses
Oncolytic viruses do not simply kill cells; rather, they are more like a "Trojan horse." To enhance the power of this "Trojan horse," Creative Biolabs' enhancement services cover multiple key dimensions:
Tumor Tropism Enhancement: For traditional vectors like adenoviruses, the platform modifies capsid proteins or utilizes tumor-specific promoters to ensure viral replication is restricted exclusively to malignant cells.
Immune Evasion and Delivery Optimization: To prevent premature clearance by the host immune system, the platform utilizes surface masking and chemical modifications, effectively "cloaking" the virus for optimized systemic delivery.
Payload Engineering: Inserting therapeutic payloads into the viral genome, such as cytokines or immune checkpoint inhibitors. According to relevant experimental data, the optimized payloads can significantly enhance the anti-tumor activity in the body.
Expert Perspective: Reimagining Treatment Paradigms Through Technological Innovation
"The potential of oncolytic viruses lies not only in their direct oncolytic effect but also in their ability to transform 'cold' tumors into 'hot' ones," said the chief scientist of Creative Biolabs when discussing the platform upgrade. "Our goal is to solve the 'last mile' delivery problem. For instance, in our enhanced oncolytic adenovirus scheme, through the synergistic optimization of virus genome attenuation and targeted modification, we can significantly balance safety and efficacy, which is crucial for clinical treatment of solid tumors."
The expert further added, "The current clinical feedback indicates that it is difficult for a single therapy to tackle complex and variable solid tumors. Therefore, our platform not only focuses on enhancing the virus itself, but also places greater emphasis on the design of combined therapies, helping clients explore the optimal synergistic effects of oncolytic viruses with chemotherapy, radiotherapy, and CAR-T therapies."
Comprehensive viral backbone support
The OncoVirapy™ platform of Creative Biolabs has established a mature enhancement system covering various types of viruses, including but not limited to:
Adenovirus: Focuses on addressing receptor-dependent limitations, significantly enhancing the systemic delivery efficiency through a one-stop adenovirus enhancement technology.
Vaccinia Virus: Utilizing its large gene capacity, it achieves simultaneous expression of multiple targets and payloads through customized vaccinia virus enhancement services.
Other vectors: Optimizes infection efficiency for specific cancer types such as herpes simplex virus (HSV) and vesicular stomatitis virus (VSV).
About
Creative Biolabs is a CRO service provider worldwide. With its profound expertise in viral engineering, cell line development, and animal model construction, the company has successfully supported hundreds of oncolytic virus projects from the early concept stage to the preclinical IND application.
Contact Info:
Name: Candy Swift
Email: Send Email
Organization: Creative Biolabs
Website: https://www.creative-biolabs.com/oncolytic-virus/
Release ID: 89181699
Google
RSS